HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

David T. Rubin  1     Freddy Caldera  2     Jeffrey Cohen  3     Stefan Zeuzem  4     Chun-Yen Cheng  5     Shabana Ather     Lorna Charles     James K. Sheffield     Axel Dignass  6    
1 University of Chicago Medicine Inflammatory Bowel Disease, Chicago, United States
2 University of Wisconsin School of Medicine and Public Health, Madison, United States
3 Cleveland Clinic, Cleveland, United States
4 Goethe University Hospital, Frankfurt, Germany
5 Bristol Myers Squibb, Princeton, United States
6 Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing